Movantik

Discussion in 'Daiichi-Sankyo' started by Anonymous, May 23, 2015 at 2:30 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest



    AZ rep here. He is actually correct. We are weighted 40 % MOV, 40% SXR and 20% Pristiq. MOV is our primary drug in the pain offices, rheumos, Orthos and some select primary care. We don't have any doctors where we detail both SXR and MOV. Well, maybe a handful. Some of our customers have Pristiq as a secondary call to MOV. And some (Psychs) have Pristiq secondary to SXR.
     

  2. Anonymous

    Anonymous Guest

    I sold sprix too. Was pretty successful with neurology but nothing else.
     
  3. Anonymous

    Anonymous Guest

    Big Mo is already up to plus 1,000 new's a week and that is really good when you compare to launches over past year, that's not bad, we have quite a few mid-levels now writing one or two a day, others not there yet but we've seen them like two times, to say a drug won't sell after two sales calls is crazy and is more about the rep then the drug or the md, go work hard for christ's sake
     
  4. Anonymous

    Anonymous Guest

    1000? Are you high?
     
  5. Anonymous

    Anonymous Guest

    Very high. Movantik is a bomb of epic proportions. And we paid $200 million just to be AZ's bitch and split the "profit" at the end of the day. What profit? This stupid deal has put us in the hole for years.
     
  6. Anonymous

    Anonymous Guest

    Movantik sales are starting to take off!$$$ Maybe DSI knows what they're doing after all! Ha!
     
  7. Anonymous

    Anonymous Guest

    Really?! It's about time!
     
  8. Anonymous

    Anonymous Guest

    Re: Movantik - - its the doc and the label

    Movantik is similar to Relistor. The Relistor molecule is naltrexone plus methyl (to keep the drug from crossing the BBB), while Movantik is naloxone plus PEG-nnnn (to keep the drug from crossing the BBB). Functionally, the two drugs are quite similar.

    A while back, when Relistor was the only game in town, I called my pain dr. to ask for Relistor. A week later, I got a response saying that the doc was unfamiliar with it and had to look it up. After doing so, he denied my request, on the basis that he maintains a strict policy of not prescribing injectables. He suggested that I ask my primary care doc.

    The primary told me he'd probably prescribe it, but he needed to review the labeling first.
    As soon as he saw the comment "Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients.", he said he'd need clearance from my GI before he would prescribe it. That later changed to "have the GI prescribe it".

    You guessed it: GI's consider it to be in the purview of pain mgmt docs.

    Never mind that "Rare cases of GI perforation have been reported in advanced illness patients does not imply a causative relationship. Even in the absence of such a relationship, any adverse event must be reported, regardless of cause.

    There is a subgroup of Crohn's patients whose disease is referred to as "perforating Crohn's". In a patient experiencing OIC, there can be increased intestinal pressure that is sometimes severe enough to cause abdominal stretch marks, even in a male. When such pressure exists in a patient with "perforating Crohn's", it would seem that a perforation incident would be more likely due to the increased pressure than due to a drug that actually reduces such pressure by relieving constipation

    Although reporting of the perforation incident can be misleading, it can't be ignored. It's impact could be alleviated, however, by a more detailed (and, hence, less misleading) description of the incident(s).
     
  9. Anonymous

    Anonymous Guest

    Great post! Agreed...DSI got this one right! Movantik is looking very good right now to say the least. Great companies find a way.